DE3751470D1 - Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen. - Google Patents

Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.

Info

Publication number
DE3751470D1
DE3751470D1 DE3751470T DE3751470T DE3751470D1 DE 3751470 D1 DE3751470 D1 DE 3751470D1 DE 3751470 T DE3751470 T DE 3751470T DE 3751470 T DE3751470 T DE 3751470T DE 3751470 D1 DE3751470 D1 DE 3751470D1
Authority
DE
Germany
Prior art keywords
pentigetide
ige
treatment
inflammatory diseases
mediated inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3751470T
Other languages
English (en)
Other versions
DE3751470T2 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dura Pharmaceuticals Inc
Original Assignee
Dura Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dura Pharmaceuticals Inc filed Critical Dura Pharmaceuticals Inc
Publication of DE3751470D1 publication Critical patent/DE3751470D1/de
Application granted granted Critical
Publication of DE3751470T2 publication Critical patent/DE3751470T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE3751470T 1986-12-09 1987-12-09 Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen. Expired - Fee Related DE3751470T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/939,927 US4816449A (en) 1984-08-09 1986-12-09 Immunotherapeutic anti-inflammatory peptide agents
PCT/US1987/003222 WO1988004177A1 (en) 1986-12-09 1987-12-09 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NON-IgE-MEDIATED DISEASES

Publications (2)

Publication Number Publication Date
DE3751470D1 true DE3751470D1 (de) 1995-09-21
DE3751470T2 DE3751470T2 (de) 1996-04-04

Family

ID=25473943

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3751470T Expired - Fee Related DE3751470T2 (de) 1986-12-09 1987-12-09 Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.

Country Status (8)

Country Link
US (1) US4816449A (de)
EP (1) EP0335901B1 (de)
JP (2) JPH02501573A (de)
AT (1) ATE126441T1 (de)
AU (2) AU1049788A (de)
DE (1) DE3751470T2 (de)
DK (2) DK442788A (de)
WO (2) WO1988004178A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061692A (en) * 1984-08-09 1991-10-29 Immunetech Pharmaceuticals Methods and compositions for the treatment of non-IgE-mediated diseases
US5468730A (en) * 1984-08-09 1995-11-21 Dura Pharmaceuticals, Inc. Methods for the treatment of non-IgE-mediated diseases
GB8905606D0 (en) * 1989-03-11 1989-04-26 Scras Peptides
DK122489D0 (da) * 1989-03-14 1989-03-14 Carlsberg Biotechnology Ltd Fremgangsmaade til fremstilling af pentapeptider samt mellemprodukter til brug ved fremstillingen
US5252464A (en) * 1989-03-14 1993-10-12 Carlsberg Biotechnology Ltd. A/S Process for producing pentapeptides and intermediates for use in the synthesis
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
US5268455A (en) * 1989-05-25 1993-12-07 Genentech, Inc. Process for making biologically active polypeptides based on transforming growth factor-βsequences
US5100378A (en) * 1989-06-09 1992-03-31 Neorx Corporation Enhancement of target cell localization of lymphoid cells
US5028593A (en) * 1989-08-15 1991-07-02 Board Of Regents, The University Of Texas System Tuftsin analogs
US5118669A (en) * 1989-09-20 1992-06-02 Hitachi Chemical Co., Ltd. Peptides and intermediates therefor useful as antiallergic agents, vasodilators and immunoregulators
US5223487A (en) * 1989-09-30 1993-06-29 Hitachi Chemical Co., Ltd. Peptides as antiallergic agents
US5776892A (en) * 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
US5250293A (en) * 1991-04-22 1993-10-05 Gleich Gerald J Method for the treatment of hypersensitivity diseases by administration of anionic polymers
US5681555A (en) * 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
US5498410A (en) * 1991-04-22 1996-03-12 Gleich; Gerald J. Method for the treatment of eosinophil-associated conditions with anionic polymers
DE69223844T2 (de) * 1991-04-24 1998-04-16 Morinaga Milk Industry Co Ltd Antimikrobielles Peptid und antimikrobieller Wirkstoff
GB9211668D0 (en) * 1992-06-02 1992-07-15 Nycomed Bioreg As Peptide compounds
US6177405B1 (en) * 1992-07-22 2001-01-23 Kenji Nishioka Cyclic analogs of tuftsin
DE4237456A1 (de) * 1992-11-06 1994-05-11 Merck Patent Gmbh Cyclopeptide
US5705481A (en) * 1992-11-06 1998-01-06 Merck Patent Gesellschaft Mit Beschrankter Haftung Cyclopeptides
IL108031A0 (en) * 1992-12-22 1994-04-12 Procter & Gamble Difluoro pentapeptide derivatives and pharmaceutical compositions containing them
CA2568107C (en) * 1993-06-18 2011-06-14 Curative Technologies, Inc. Anti-inflammatory peptides
GB9320897D0 (en) * 1993-10-11 1993-12-01 Peptide Therapeutics Ltd Compounds useful in anti-allergy treatment
US6139850A (en) * 1994-12-21 2000-10-31 Cosmederm Technologies Formulations and methods for reducing skin irritation
US7404967B2 (en) * 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
GB9509957D0 (en) * 1995-05-17 1995-07-12 Khalil Nasreen Post-translational activation of tgf-›1 involving the tsp-1 receptor cd36
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
AU749471B2 (en) 1998-01-20 2002-06-27 Myriad Genetics, Inc. MMSC1 - an MMAC1 interacting protein
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
DE69940805D1 (de) * 1998-01-31 2009-06-10 Sinai School Medicine Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie
US6767890B1 (en) * 1998-11-18 2004-07-27 Coastside Bio Resources Peptides having anti-cancer and anti-inflammatory activity
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US20030130185A1 (en) * 2000-09-29 2003-07-10 David Bar-Or Metal-binding compounds and uses therefor
US20030158111A1 (en) * 1999-10-01 2003-08-21 David Bar-Or Methods and products for oral care
US7592304B2 (en) * 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
CA2403292C (en) * 2000-04-06 2011-02-08 Panacea Pharmaceuticals, Llc Microbial delivery system
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US6908899B2 (en) * 2001-08-17 2005-06-21 U.S. Dept. Of Veterans Affairs Pro-inflammatory fibrinopeptide
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
WO2003018619A2 (en) 2001-08-24 2003-03-06 Micrologix Biotech Inc. Antimicrobial and anti-inflammatory peptides
BR0212256A (pt) * 2001-08-30 2004-08-31 Biorexis Pharmaceutical Corp Proteìnas de fusão de transferrina modificadas
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US20070031440A1 (en) * 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
ES2347144T3 (es) * 2002-08-30 2010-10-26 Biorexis Pharmaceutical Corporation Proteinas de fusion de la transferrina modificada que comprenden dominos aino o carboxilo de transferrina duplicados.
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
ES2330516T3 (es) * 2002-11-20 2009-12-11 Prometic Biosciences Inc. Composicion para el tratamiento de la ictiosis que utiliza la antitripsina.
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
BRPI0410505A (pt) * 2003-05-07 2006-06-20 Dmi Biosciences Inc métodos e produtos para cuidados orais
WO2005021579A2 (en) * 2003-08-28 2005-03-10 Biorexis Pharmaceutical Corporation Epo mimetic peptides and fusion proteins
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
AU2004275821A1 (en) * 2003-09-25 2005-04-07 Dmi Biosciences Inc. Methods and products which utilize N-acyl-L-aspartic acid
EP1568707A1 (de) * 2004-02-26 2005-08-31 Puleva Biotech, S.A. Blutdrucksenkenden Peptiden aus Kaseinhydrolysaten
CN101511868B (zh) * 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
US8697840B2 (en) * 2008-03-05 2014-04-15 Board Of Regents, The University Of Texas System Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
CN117679487A (zh) 2013-03-15 2024-03-12 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
KR101632948B1 (ko) * 2014-05-13 2016-06-27 (주)케어젠 항염증, 골 형성 및 발모 촉진 활성을 갖는 펩타이드 및 이의 용도
BR112021004404A2 (pt) 2018-09-10 2021-08-03 Lung Therapeutics, Inc. fragmentos de peptídeos modificados da proteína cav-1 e o uso destes no tratamento de fibrose
JP2022527901A (ja) 2019-03-26 2022-06-07 インターナショナル フレーバーズ アンド フラグランシズ インコーポレイテッド ざ瘡が起こりやすい皮膚およびざ瘡性皮膚の予防および管理におけるポリリシンデンドリマーの使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065808A (en) * 1975-01-25 1977-12-27 U.S. Philips Corporation Network computer system
US4171299A (en) * 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
DE2602443A1 (de) * 1975-04-04 1976-10-21 Univ California Biologisch aktive polypeptide
US4392997A (en) * 1981-07-06 1983-07-12 Northwestern University Antigenic peptide compounds
US4814973A (en) * 1983-05-31 1989-03-21 Hillis W Daniel Parallel processor
US4686282A (en) * 1983-08-12 1987-08-11 Immunetech, Inc. Immunotherapeutic polypeptide agents which block immune complex binding to immunoglobulin Fc receptors
US4579840A (en) * 1983-08-12 1986-04-01 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin Fc receptors
US4683292A (en) * 1983-08-12 1987-07-28 Immunetech, Inc. Immunotherapeutic polypeptide agents which bind to lymphocyte immunoglobulin FC receptors
JPH07120275B2 (ja) * 1983-12-28 1995-12-20 株式会社日立製作所 シミューションプログラム生成方法
US4692511A (en) * 1984-07-03 1987-09-08 Immunetech Pharmaceuticals Peptide antagonists for the C5a anaphylatoxin
ZA846192B (en) * 1984-08-09 1986-03-26 Merck Patent Gmbh Immunotherapeutic polypeptide agents

Also Published As

Publication number Publication date
DK442688D0 (da) 1988-08-08
DK442688A (da) 1988-10-07
WO1988004178A1 (en) 1988-06-16
AU612341B2 (en) 1991-07-11
EP0335901A1 (de) 1989-10-11
US4816449A (en) 1989-03-28
ATE126441T1 (de) 1995-09-15
JPH02501066A (ja) 1990-04-12
JPH02501573A (ja) 1990-05-31
WO1988004177A1 (en) 1988-06-16
DK442788D0 (da) 1988-08-08
DK442788A (da) 1988-10-07
EP0335901A4 (en) 1990-11-28
AU1056788A (en) 1988-06-30
EP0335901B1 (de) 1995-08-16
DE3751470T2 (de) 1996-04-04
AU1049788A (en) 1988-06-30

Similar Documents

Publication Publication Date Title
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
DE69024039D1 (de) Behandlung von pathologischen zuständen und krankheiten.
DE69124293T2 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
DE3884622T2 (de) Schmiermittelzubereitung zur behandlung von rheuma.
DE3685633D1 (de) Behandlung von knochenstoerungen.
DE3587741D1 (de) Behandlung von Hautkrankheiten.
DE3578611D1 (de) Instrumente zur behandlung von verformten naegeln bei menschlichen patienten.
DE3750934T2 (de) Behandlung von nicht-Akne-entzündlichen und -infektiösen Hautkrankheiten.
DE68910175T3 (de) Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut.
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
PT77020A (de) Mittel zur behandlung von wunden
DE3785555D1 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
DE68908445T2 (de) Mittel zur Behandlung von Lebererkrankungen.
ATA84689A (de) Einrichtung zur behandlung von gasen
ATE95061T1 (de) Schmiermittelzubereitung zur behandlung von rheuma.
DE3673017D1 (de) Vorrichtung zur behandlung von gliedmassen.
ATE91889T1 (de) Verfahren zur behandlung von brandwunden.
ATE91886T1 (de) Praeparat zur behandlung von erektionsstoerungen.
ATE86857T1 (de) Transdermate magensafthemmende wirkstoffe zur behandlung von magen-darm-erkrankungen.
DE3771706D1 (de) Behandlung von knochenschwund.
ATE84435T1 (de) Einrichtung zur behandlung von gasen.
ATE85522T1 (de) Mittel zur behandlung von chronisch entzuendlichen darmerkrankungen.
ATE65394T1 (de) Behandlung von knochenschwund.
DE68906028T2 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee